Abstract
In this issue of Cancer Discovery, He and colleagues determined that Mcl-1 levels are a key factor in the response to histone deacetylase (HDAC) inhibitors, and FBXW7 mutation is a biomarker for sensitivity to HDAC inhibition. They also present evidence for synergy between treatment with HDAC inhibitors and Bcl-2- targeted therapeutics. These data provide an exciting new biomarker and combination therapy that should be evaluated clinically.
Original language | English (US) |
---|---|
Pages (from-to) | 258-259 |
Number of pages | 2 |
Journal | Cancer discovery |
Volume | 3 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2013 |
ASJC Scopus subject areas
- Oncology